ARKG vs. CNCR

Last updated Jun 4, 2026

ARKG (ARK Genomic Revolution Multi-Sector ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds. ARKG is actively managed, while CNCR is passively managed. ARKG charges 0.75%/yr vs 0.79%/yr for CNCR.

Performance

ARKG vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

ARKG

• 1D: -0.24%
• 1M: 10.92%
• YTD: 17.09%
• 6M: 10.02%
• 1Y: 53.35%
• 3Y*: 0.67%
• 5Y*: -15.72%
• 10Y*: 7.22%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
ARKG ARK Genomic Revolution Multi-Sector ETF	17.82%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

ARKG vs. CNCR - Sectors Allocation Comparison

Sectors	ARKG	CNCR
Healthcare	99.2%	96.6%
Financial Services	0.5%	3.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

ARKG vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARKG

ARKG Risk / Return Rank: 35
ARKG Sharpe Ratio Rank: 35
ARKG Sortino Ratio Rank: 37
ARKG Omega Ratio Rank: 32
ARKG Calmar Ratio Rank: 38
ARKG Martin Ratio Rank: 31

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARKG	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	1.31	—	—
Sortino ratio: Return per unit of downside risk	1.99	—	—
Omega ratio: Gain probability vs. loss probability	1.22	—	—
Calmar ratio: Return relative to maximum drawdown	1.95	—	—
Martin ratio: Return relative to average drawdown	4.67	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	ARKG	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.31	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.18	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.13	—	—

Drawdowns

ARKG vs. CNCR - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for ARKG and CNCR.

Drawdown Indicators

	ARKG	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-83.59%	0.00%	-83.59%
Max Drawdown (1Y) Largest decline over 1 year	-27.51%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-51.96%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-80.18%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-83.59%	—	—
Current Drawdown Current decline from peak	-69.65%	0.00%	-69.65%
Average Drawdown Average peak-to-trough decline	-35.87%	0.00%	-35.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.46%	—	—

Volatility

Volatility by Period

	ARKG	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.90%	—	—
Volatility (6M) Calculated over the trailing 6-month period	28.77%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	41.12%	0.00%	+41.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.61%	0.00%	+45.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	41.12%	0.00%	+41.12%

ARKG vs. CNCR - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

ARKG vs. CNCR - Dividend Comparison

Neither ARKG nor CNCR has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.62%	0.85%	3.14%	0.82%	1.34%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, ARKG or CNCR?

On fees, ARKG is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, ARKG or CNCR?

ARKG is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, ARKG or CNCR?

ARKG and CNCR have nearly identical dividend yields, around 0.00%.

What is the main difference between ARKG and CNCR?

They also come from different issuers: ARK and Exchange Traded Concepts. Their fees differ too: 0.75% for ARKG and 0.79% for CNCR.